

Development of an Inactivated Vaccine Candidate, BBIP against SARS-CoV-2

Cell

182, 713-721.e9

DOI: [10.1016/j.cell.2020.06.008](https://doi.org/10.1016/j.cell.2020.06.008)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Adjuvants for Coronavirus Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 589833.	2.2	145
2	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 583252.	1.5	18
3	Coronavirus disease-19 vaccine development utilizing promising technology. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 351-358.	1.5	4
4	A systematic review of SARS-CoV-2 vaccine candidates. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 237.	7.1	427
5	SARS-CoV-2 vaccines in development. <i>Nature</i> , 2020, 586, 516-527.	13.7	1,659
6	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> , 2020, 183, 996-1012.e19.	13.5	1,494
7	Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. <i>Cell Discovery</i> , 2020, 6, 68.	3.1	132
8	Virus Irradiation and COVID-19 Disease. <i>Frontiers in Physics</i> , 2020, 8, .	1.0	16
9	Severe acute respiratory syndrome coronavirusâ€2 natural animal reservoirs and experimental models: systematic review. <i>Reviews in Medical Virology</i> , 2021, 31, e2196.	3.9	24
10	Bacillus Calmetteâ€“GuÃ©rin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally. <i>Vaccine</i> , 2020, 38, 7629-7637.	1.7	2
11	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. <i>Immunity</i> , 2020, 53, 1315-1330.e9.	6.6	215
12	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. <i>Emerging Microbes and Infections</i> , 2020, 9, 2606-2618.	3.0	28
13	A safety consideration of mesenchymal stem cell therapy on COVID-19. <i>Stem Cell Research</i> , 2020, 49, 102066.	0.3	22
14	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
15	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
16	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
17	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 951.	3.8	671
18	Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. <i>Computers in Biology and Medicine</i> , 2020, 124, 103967.	3.9	62

#	ARTICLE	IF	CITATIONS
19	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 579250.	2.2	72
20	A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool. <i>Biomolecules</i> , 2020, 10, 1438.	1.8	4
21	Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19. <i>Clinical and Translational Medicine</i> , 2020, 10, e184.	1.7	8
22	The Current Status of COVID-19 Vaccines. <i>Frontiers in Genome Editing</i> , 2020, 2, 579297.	2.7	25
23	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 585354.	2.2	384
24	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020, 20, 615-632.	10.6	806
25	Efforts towards a COVID-19 vaccine. <i>Environmental Microbiology</i> , 2020, 22, 4071-4084.	1.8	16
26	Comparison of nonhuman primates identified the suitable model for COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 157.	7.1	190
27	An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. <i>Nature Communications</i> , 2020, 11, 4207.	5.8	194
28	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
29	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30
30	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
31	Coronavirus pandemic: treatment and future prevention. <i>Future Microbiology</i> , 2020, 15, 1507-1521.	1.0	2
32	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. <i>Vaccines</i> , 2020, 8, 649.	2.1	42
33	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	1.5	79
34	Third-Party Materials. , 2020, , 144-144.		0
35	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. <i>Journal of Biological Chemistry</i> , 2021, 296, 100025.	1.6	43
36	Temporal Strategies and Firms' Speedy Responses to COVID-19. <i>Journal of Management Studies</i> , 2021, 58, 592-596.	6.0	28

#	ARTICLE	IF	CITATIONS
37	Animal coronaviruses and SARS-CoV-2. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1097-1110.	1.3	33
38	SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-gal antibodies: A minireview and proposals. <i>Journal of Medical Virology</i> , 2021, 93, 351-356.	2.5	13
39	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 39-51.	4.6	923
40	A promising inactivated whole-virion SARS-CoV-2 vaccine. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 2-3.	4.6	15
41	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.	13.6	126
42	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. <i>Vaccine</i> , 2021, 39, 197-201.	1.7	67
43	Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3408-3424.	1.1	16
44	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
45	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	6.6	62
46	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
47	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 137-144.	1.0	12
48	SARS-CoV-2 vaccine candidates in rapid development. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 644-653.	1.4	30
49	Live unattenuated vaccines for controlling viral diseases, including COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 1943-1949.	2.5	4
50	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28
51	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. <i>Emerging Microbes and Infections</i> , 2021, 10, 1589-1597.	3.0	41
52	Effectiveness of the BBIBP-CorV Vaccine in Preventing Infection and Death in Health Care Workers in Peru 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
54	The role and uses of antibodies in COVID-19 infections: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab003.	1.2	17
55	Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. <i>Emerging Microbes and Infections</i> , 2021, 10, 1790-1806.	3.0	58

#	ARTICLE	IF	CITATIONS
57	COVID-19: Characteristics and Therapeutics. <i>Cells</i> , 2021, 10, 206.	1.8	177
58	An overview of current COVID-19 vaccine platforms. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2508-2517.	1.9	99
59	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
60	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
62	Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects. <i>Oncotarget</i> , 2021, 12, 2476-2488.	0.8	7
63	SARS-CoV-2 vaccine development and how Brazil is contributing. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200320.	0.6	7
64	Authors' response. <i>Indian Journal of Medical Research</i> , 2021, 153, 703.	0.4	0
65	Heterogeneity in protocols for bronchoalveolar lavage & sub-genomic RNA evaluation in non-human primate studies of SARS-CoV-2 vaccine candidates' evaluation. <i>Indian Journal of Medical Research</i> , 2021, 153, 702.	0.4	0
67	Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. <i>Emerging Microbes and Infections</i> , 2021, 10, 1751-1759.	3.0	206
68	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
69	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 411-432.	0.4	11
70	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000063.	1.7	5
71	Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. <i>ACS Nano</i> , 2021, 15, 2738-2752.	7.3	143
72	Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development. <i>Radiation Research</i> , 2021, 195, 221-229.	0.7	10
73	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. <i>Emerging Microbes and Infections</i> , 2021, 10, 1881-1889.	3.0	10
74	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
75	Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
78	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. <i>PLoS Biology</i> , 2021, 19, e3001091.	2.6	163

#	ARTICLE	IF	CITATIONS
79	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20
80	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
81	Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response. <i>Vaccine</i> , 2021, 39, 1241-1247.	1.7	22
83	In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. <i>Viruses</i> , 2021, 13, 379.	1.5	53
84	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
86	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1626.	1.2	17
87	Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. <i>IScience</i> , 2021, 24, 102054.	1.9	70
88	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 48.	7.1	79
89	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. <i>Npj Vaccines</i> , 2021, 6, 28.	2.9	507
90	SARS-CoV-2 virus: Vaccines in development. <i>Fundamental Research</i> , 2021, 1, 131-138.	1.6	12
91	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. <i>Scientific Reports</i> , 2021, 11, 5934.	1.6	26
92	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. <i>Frontiers in Immunology</i> , 2021, 12, 637982.	2.2	9
95	Development of COVID-19 vaccines utilizing gene therapy technology. <i>International Immunology</i> , 2021, 33, 521-527.	1.8	19
96	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. <i>Science Advances</i> , 2021, 7, .	4.7	80
97	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 1-9.	0.8	13
99	Failla Memorial Lecture: The Many Facets of Heavy-Ion Science. <i>Radiation Research</i> , 2021, 195, 403-411.	0.7	3
101	COVID-19 vaccines: rapid development, implications, challenges and future prospects. <i>Human Cell</i> , 2021, 34, 711-733.	1.2	227
102	Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders. <i>Ophthalmology and Therapy</i> , 2021, 10, 201-209.	1.0	21

#	ARTICLE	IF	CITATIONS
103	Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 1386.	5.8	74
104	An overview of vaccine development for COVID-19. <i>Therapeutic Delivery</i> , 2021, 12, 235-244.	1.2	51
105	CURRENT UPDATES ON COVID-19 VACCINES. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 17-23.	0.3	5
106	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	13.5	154
107	Low COVID-19 Vaccine Acceptance Is Correlated with Conspiracy Beliefs among University Students in Jordan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2407.	1.2	129
109	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11
110	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <i>Stem Cell Reports</i> , 2021, 16, 398-411.	2.3	18
111	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
112	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. <i>Vaccines</i> , 2021, 9, 214.	2.1	33
113	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. <i>Science Advances</i> , 2021, 7, .	4.7	100
115	How to Understand Herd Immunity in the Context of COVID-19. <i>Viral Immunology</i> , 2021, 34, 174-181.	0.6	17
116	Saliva: What Dental Practitioners Should Know about the Role of This Biofluid in the Transmission and Diagnostic of SARS-CoV-2. <i>Medicina (Lithuania)</i> , 2021, 57, 349.	0.8	3
117	Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000.	0.2	0
118	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. <i>Virus Research</i> , 2021, 295, 198305.	1.1	14
119	COVID-19 immunity and vaccines: what a pharmacist needs to know. <i>Asian Biomedicine</i> , 2021, 15, 51-67.	0.2	0
120	Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine. <i>Protein and Cell</i> , 2021, 12, 818-823.	4.8	10
122	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021, 66, 103291.	2.7	15
124	Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. <i>IScience</i> , 2021, 24, 102298.	1.9	70

#	ARTICLE	IF	CITATIONS
125	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	2.2	81
126	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32
127	Immunogenicity and efficacy of one and two doses of Ad26.COVS.S COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	55
128	Status Report on COVID-19 Vaccines Development. <i>Current Infectious Disease Reports</i> , 2021, 23, 9.	1.3	56
129	Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111272.	2.5	84
130	Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates. <i>Virologica Sinica</i> , 2021, 36, 879-889.	1.2	17
131	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. <i>Cell Reports Medicine</i> , 2021, 2, 100230.	3.3	99
132	The importance of genomic analysis in cracking the coronavirus pandemic. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 547-562.	1.5	14
135	Avoiding culture shock with the SARS-CoV-2 spike protein. <i>ELife</i> , 2021, 10, .	2.8	8
137	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
138	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 1002-1015.	3.0	22
139	Delivery Routes for COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 524.	2.1	37
141	Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19. <i>Journal of Virology</i> , 2021, 95, .	1.5	27
142	Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. <i>Vaccines</i> , 2021, 9, 556.	2.1	140
143	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. <i>Nature Communications</i> , 2021, 12, 2623.	5.8	64
144	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 35-45.	3.8	634
145	Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. <i>Expert Review of Vaccines</i> , 2021, 20, 891-898.	2.0	67
146	COVID-19 Vaccinated Individuals Can Be a Source of SARS-CoV-2 Transmission—A Systematic Review. <i>Hygiene</i> , 2021, 1, 1-11.	0.5	1

#	ARTICLE	IF	CITATIONS
147	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
148	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
149	Advances of nanomaterialsâ€based strategies for fighting against COVIDâ€19. <i>View</i> , 2021, 2, 20200180.	2.7	16
150	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. <i>Journal of Infectious Diseases</i> , 2021, 224, 407-414.	1.9	43
151	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628585.	1.6	31
152	Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice. <i>Pathogens</i> , 2021, 10, 626.	1.2	7
153	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. <i>Vaccines</i> , 2021, 9, 520.	2.1	28
154	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 213.	7.1	76
155	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
156	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
157	Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. <i>Journal of Inorganic Biochemistry</i> , 2021, 219, 111454.	1.5	29
159	Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt. <i>Antibody Therapeutics</i> , 2021, 4, 135-143.	1.2	1
160	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
161	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
162	SARS-CoV-2 vaccines, where do we stand?. <i>Comptes Rendus - Biologies</i> , 2021, 344, 43-55.	0.1	3
163	State of assisted reproduction technology in the coronavirus disease 2019 era and consequences on human reproductive system. <i>Biology of Reproduction</i> , 2021, 105, 808-821.	1.2	14
164	SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. <i>Vaccines</i> , 2021, 9, 706.	2.1	14
165	Low-dose Ad26.COVS.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49

#	ARTICLE	IF	CITATIONS
166	The first Chinese national standards for SARS-CoV-2 neutralizing antibody. <i>Vaccine</i> , 2021, 39, 3724-3730.	1.7	8
167	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
168	Animal models for SARS-CoV-2. <i>Current Opinion in Virology</i> , 2021, 48, 73-81.	2.6	52
170	Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development. <i>Vaccines</i> , 2021, 9, 613.	2.1	5
171	Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update. <i>Stem Cells International</i> , 2021, 2021, 1-16.	1.2	7
172	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
173	Role of nanotechnology behind the success of mRNA vaccines for COVID-19. <i>Nano Today</i> , 2021, 38, 101142.	6.2	170
174	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
176	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
178	A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 186-193.	1.8	19
179	A Brief Overview of COVID-19 Vaccines. <i>Iranian Journal of Public Health</i> , 2021, 50, i-vi.	0.3	6
180	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
181	Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 356, 577599.	1.1	62
182	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
183	A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19. <i>Vaccines</i> , 2021, 9, 718.	2.1	18
184	Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5 α -based COVID-19 vaccine. <i>Science Advances</i> , 2021, 7, .	4.7	60
185	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
186	A dossier on COVID-19 chronicle. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 45-54.	0.7	3

#	ARTICLE	IF	CITATIONS
187	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
188	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	180
189	Are We Paving the Way to Dig Out of the "Pandemic Hole"? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 53.	1.3	1
190	Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	12
192	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. <i>Cell Research</i> , 2021, 31, 1011-1023.	5.7	48
194	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. <i>Lancet, The</i> , 2021, 398, 213-222.	6.3	683
195	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
196	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
198	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
199	A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates. <i>Innovation(China)</i> , 2021, 2, 100140.	5.2	19
200	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 910.	2.1	50
201	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
202	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. <i>Cell Discovery</i> , 2021, 7, 67.	3.1	29
203	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
204	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
205	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. <i>Frontiers in Microbiology</i> , 2021, 12, 722178.	1.5	5
206	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
207	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15

#	ARTICLE	IF	CITATIONS
208	Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. <i>Infectious Microbes & Diseases</i> , 2021, 3, 125-133.	0.5	0
209	Acute Uveitis following COVID-19 Vaccination. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1207-1209.	1.0	65
211	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. <i>International Immunopharmacology</i> , 2021, 97, 107679.	1.7	9
212	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	23
213	A Self-Biomineralized Novel Adenovirus Vected COVID-19 Vaccine for Boosting Immunization of Mice. <i>Virologica Sinica</i> , 2021, 36, 1113-1123.	1.2	11
214	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 196-208.	4.6	147
215	An ultrapotent pan- \hat{I}^2 -coronavirus lineage B (\hat{I}^2 -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
216	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
217	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
218	Immunogenicity and Safety Analysis of Inactivated Virus Vaccine against SARS-CoV-2: A Systematic Review of Phase 1/2 Clinical Trials. <i>Journal of Asian Medical Student Association</i> , 2021, 9, .	0.1	0
219	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. <i>Microbiology Spectrum</i> , 2021, 9, e0073321.	1.2	22
220	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. <i>Frontiers in Immunology</i> , 2021, 12, 652252.	2.2	13
221	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. <i>Vaccines</i> , 2021, 9, 1028.	2.1	11
222	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
223	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
224	Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1936.	1.5	9
225	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
226	Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque. <i>Vaccines</i> , 2021, 9, 1007.	2.1	14

#	ARTICLE	IF	CITATIONS
227	Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues. <i>Journal of Virology</i> , 2021, 95, e0153721.	1.5	38
228	A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. <i>Vaccine</i> , 2021, 39, 6520-6528.	1.7	97
229	Side effects and perceptions following Sinopharm COVID-19 vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 111, 219-226.	1.5	157
230	MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103225.	0.9	16
231	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
232	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18
233	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100026.	1.7	21
234	What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. <i>Journal of Korean Medical Science</i> , 2021, 36, e54.	1.1	24
235	Carbon-based nanomaterials for viral infection management. <i>Biomicrofluidics</i> , 2021, 15, 011501.	1.2	12
236	A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. <i>RSC Advances</i> , 2021, 11, 20006-20035.	1.7	6
237	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. <i>Biomolecules</i> , 2021, 11, 196.	1.8	4
238	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. <i>Immune Network</i> , 2021, 21, e8.	1.6	3
239	Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. <i>Zoological Research</i> , 2021, 42, 170-181.	0.9	3
240	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <i>Molecular Biomedicine</i> , 2021, 2, 1.	1.7	20
241	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	1.2	60
242	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
244	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
245	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995

#	ARTICLE	IF	CITATIONS
246	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Nature</i> , 2021, 590, 320-325.	13.7	148
261	A review of COVID-19 vaccines in development: 6 months into the pandemic. <i>Pan African Medical Journal</i> , 2020, 37, 124.	0.3	6
262	Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
263	COVID-19 in China: From epidemiology to treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	4
264	Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. <i>Indian Journal of Medical Research</i> , 2021, 153, 93.	0.4	28
265	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
266	Detección de anticuerpos neutralizantes en profesionales de la salud vacunados contra el SARS-CoV-2. <i>Horizonte Médico</i> , 2021, 21, e1539.	0.1	1
267	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23
268	Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. <i>Annual Review of Medicine</i> , 2022, 73, 55-64.	5.0	55
269	Innovations and development of Covid-19 vaccines: A patent review. <i>Journal of Infection and Public Health</i> , 2022, 15, 123-131.	1.9	27
270	Survey on individual experiences after first dose of COVID-19 vaccination amongst Indian oral health care personnel. <i>The Journal of Community Health Management</i> , 2021, 8, 119-123.	0.1	2
271	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
272	Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. <i>GeroScience</i> , 2021, 43, 2321-2331.	2.1	59
274	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
275	Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. <i>Journal of Integrative Medicine</i> , 2022, 20, 34-44.	1.4	52
277	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. <i>Cell Reports Medicine</i> , 2021, 2, 100448.	3.3	11
278	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
280	Development of synthetic antigen vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3855-3870.	1.4	4

#	ARTICLE	IF	CITATIONS
281	The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination. <i>Clinical Immunology Communications</i> , 2021, 1, 13-16.	0.5	19
282	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112282.	2.5	10
283	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
284	Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31
285	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
286	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. <i>Journal of Thoracic Disease</i> , 2020, 12, 7454-7466.	0.6	1
288	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
289	Sinopharm's BBIBP-CorV Vaccine Effectiveness on Preventing Hospital Admission and Deaths: Results From a Retrospective Study in the Emirate of Abu Dhabi, United Arab Emirates (UAE). <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
290	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
291	Vaccine and vaccination as a part of human life: In view of Covid-19. <i>Biotechnology Journal</i> , 2021, 17, 2100188.	1.8	9
292	Development of Inactivated FAKHRAVAC [®] Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models. <i>Vaccines</i> , 2021, 9, 1271.	2.1	18
293	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.4	15
294	An Update on Animal Models for Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Countermeasure Development. <i>Frontiers in Microbiology</i> , 2021, 12, 770935.	1.5	4
295	Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models. <i>Emerging Microbes and Infections</i> , 2021, 10, 2194-2198.	3.0	10
296	Development of an Inactivated Vaccine against SARS CoV-2. <i>Vaccines</i> , 2021, 9, 1266.	2.1	23
297	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. <i>Vaccines</i> , 2021, 9, 1261.	2.1	10
298	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26
302	Innovative recombinant protein-based vaccines against SARS-CoV-2. , 2022, , 193-211.		1

#	ARTICLE	IF	CITATIONS
303	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
304	Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology. Bulletin of Experimental Biology and Medicine, 2021, 172, 49-52.	0.3	2
305	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiology Spectrum, 2021, 9, e0139721.	1.2	15
306	Suppression and Activation of Intracellular Immune Response in Initial Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Frontiers in Microbiology, 2021, 12, 768740.	1.5	1
307	Microneedles enable the development of skin-targeted vaccines against coronaviruses and influenza viruses. Pharmaceutical Development and Technology, 2022, 27, 83-94.	1.1	3
308	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 2021, 9, 1387.	2.1	51
309	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	1.4	16
310	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. Frontiers in Immunology, 2021, 12, 771242.	2.2	15
311	Covidâ€19 vaccines and variants of concern: A review. Reviews in Medical Virology, 2022, 32, e2313.	3.9	201
312	Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. Cell Discovery, 2021, 7, 112.	3.1	14
313	Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic. Russian Journal of Infection and Immunity, 2021, 11, 887-904.	0.2	9
315	The development of Chinaâ€™s vaccine industry in the past decade: the perspective from drug regulatory science. Human Vaccines and Immunotherapeutics, 2024, 17, 5666-5672.	1.4	4
316	COVID-19 variants that escape vaccine immunity: Global and Indian contextâ€are more vaccines needed?. Journal of Biosciences, 2021, 46, 1.	0.5	2
317	Research Progress on a SARS-CoV-2 Vaccine in China. Journal of Biosciences and Medicines, 2021, 09, 76-88.	0.1	1
318	Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines, 2022, 10, 86.	2.1	62
319	Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine, 2022, 43, 101226.	3.2	52
320	Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies: a systematic review. Open Research Europe, 0, 2, 4.	2.0	0
321	Toxicity of spike fragments SARS-CoV-2 S protein for zebrafish: A tool to study its hazardous for human health?. Science of the Total Environment, 2022, 813, 152345.	3.9	19

#	ARTICLE	IF	CITATIONS
322	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. <i>Cell and Bioscience</i> , 2021, 11, 202.	2.1	13
323	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
324	Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations. <i>Chemical Papers</i> , 2022, 76, 2759-2776.	1.0	28
325	Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
326	Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19. <i>Irish Journal of Medical Science</i> , 2022, 191, 2833-2838.	0.8	1
328	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
329	Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations. <i>Pathogens</i> , 2022, 11, 171.	1.2	4
330	Trimeric S protein COVID-19 vaccine needs to find its place. <i>Lancet, The</i> , 2022, 399, 415-417.	6.3	1
332	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
333	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
334	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
335	Common Side Effects of COVID-19 Vaccines Used in Iran: A Review. <i>Annals of Military and Health Sciences Research</i> , 2022, 19, .	0.1	1
336	Plant-Based Vaccines in Combat against Coronavirus Diseases. <i>Vaccines</i> , 2022, 10, 138.	2.1	13
337	The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates. <i>Scientific Reports</i> , 2022, 12, 490.	1.6	10
338	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. <i>Journal of Medical Virology</i> , 2022, 94, 2369-2375.	2.5	24
339	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
340	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-16.	0.7	2
341	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 789882.	1.5	20

#	ARTICLE	IF	CITATIONS
342	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals – EAAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
344	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
345	Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 414.	7.1	91
347	Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. <i>Infectious Diseases of Poverty</i> , 2021, 10, 138.	1.5	16
348	COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	0
349	Dynamics of specific antibodies in COVID-19 patients after recovery. <i>Epidemiology and Infection</i> , 2022, 150, 1-27.	1.0	0
350	Review on Approved and Inprogress COVID-19 Vaccines. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.3	6
351	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
352	Vaccine types and reverse vaccinology. , 2022, , 31-55.		1
353	Rare-earth ions as antibacterial agents for woven wool fabric. <i>Chemical Papers</i> , 2022, 76, 3557-3567.	1.0	5
355	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. <i>Frontiers in Immunology</i> , 2022, 13, 844837.	2.2	13
356	Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	10
357	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 142.	2.4	24
358	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
359	A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca. <i>Vaccines</i> , 2022, 10, 292.	2.1	5
360	The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants. <i>Viruses</i> , 2022, 14, 489.	1.5	7
361	Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 857779.	2.2	12
362	Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). <i>Vaccine</i> , 2022, 40, 2003-2010.	1.7	39

#	ARTICLE	IF	CITATIONS
363	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
364	The Prevalence of COVID-19 Infection in Students and Staff at a Private University in Thailand by Rapid SARS-CoV-2 Antigen Detection Assay. <i>Journal of Environmental and Public Health</i> , 2022, 2022, 1-7.	0.4	0
365	Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and <i>Streptococcus pneumoniae</i> . <i>Advanced Materials</i> , 2022, 34, e2200443.	11.1	11
366	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. <i>Journal of Microbiology</i> , 2022, 60, 308-320.	1.3	6
367	Uveitis after COVID-19 Vaccination. <i>Case Reports in Ophthalmology</i> , 2022, 13, 124-127.	0.3	7
368	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
369	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1372-1381.	1.9	41
370	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2166-2185.	1.1	3
372	The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. <i>Open Microbiology Journal</i> , 2022, 16, .	0.2	1
373	Anti-SARS-CoV-2 equine F (Ab) ² immunoglobulin as a possible therapy for COVID-19. <i>Scientific Reports</i> , 2022, 12, 3890.	1.6	8
374	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. <i>View</i> , 2022, 3, .	2.7	8
375	Various vaccine platforms in the field of COVID-19. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, 35.	0.8	10
376	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. <i>Npj Vaccines</i> , 2022, 7, 31.	2.9	21
377	Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2404-2414.	2.7	34
378	Association of severity and mortality of Covid-19 cases among acute kidney injury and sexual dimorphism. <i>Molecular Biology Reports</i> , 2022, 49, 6753-6762.	1.0	1
379	Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice. <i>Frontiers in Microbiology</i> , 2022, 13, 792532.	1.5	11
380	COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. <i>Bulletin of the National Research Centre</i> , 2022, 46, 96.	0.7	25
381	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1

#	ARTICLE	IF	CITATIONS
382	Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats. <i>Toxicology</i> , 2022, 471, 153161.	2.0	3
383	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
384	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. <i>Frontiers in Immunology</i> , 2022, 13, 882856.	2.2	4
385	Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. <i>Frontiers in Immunology</i> , 2022, 13, 882972.	2.2	32
386	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
387	Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Molecular Biology</i> , 2021, 55, 889-898.	0.4	12
389	The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 758294.	2.2	43
390	Clustering cases of <i>Chlamydia psittaci</i> pneumonia mimicking COVID-19 pneumonia. <i>World Journal of Clinical Cases</i> , 2021, 9, 11237-11247.	0.3	4
391	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
394	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. <i>GeroScience</i> , 2022, 44, 57-61.	2.1	3
395	Current aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practice. <i>Problemy Zdorov'ia i Ākologii</i> , 2021, 18, 5-16.	0.0	0
396	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
397	Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. <i>Frontiers in Immunology</i> , 2021, 12, 802858.	2.2	32
398	Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2. <i>ACS Omega</i> , 2022, 7, 3203-3211.	1.6	21
399	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
400	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. <i>Exploration of Immunology</i> , 0, , 440-460.	1.7	0
401	SARS-CoV-2 Inactivation Simulation Using 14 MeV Neutron Irradiation. <i>Life</i> , 2021, 11, 1372.	1.1	5
402	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2R ³ cKO.NOD) for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	6

#	ARTICLE	IF	CITATIONS
403	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. The Egyptian Journal of Internal Medicine, 2022, 34, 34.	0.3	5
404	Ischemic colitis after receiving the second dose of a COVID-19 inactivated vaccine: A case report. World Journal of Clinical Cases, 2022, 10, 3866-3871.	0.3	5
405	An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. Journal of Clinical Laboratory Analysis, 2022, 36, e24418.	0.9	39
406	Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old. Vaccines, 2022, 10, 586.	2.1	7
407	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. PLoS Pathogens, 2022, 18, e1010155.	2.1	6
408	Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Journal of Clinical Virology, 2022, 150-151, 105161.	1.6	8
409	A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, 47.	2.9	6
410	Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS ONE, 2022, 17, e0267102.	1.1	15
411	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. Frontiers in Immunology, 2022, 13, 804945.	2.2	12
413	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. Future Virology, 2022, 17, 403-413.	0.9	6
414	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10
415	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Frontiers in Immunology, 2022, 13, 843928.	2.2	25
416	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	3.9	17
417	Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029.		26
418	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
419	Vaccines for Covid-19: An insight on their effectiveness and adverse effects. Journal of Medical Virology, 2022, , .	2.5	7
420	A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines, 2022, 10, 737.	2.1	8
421	SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges. Exploration of Immunology, 0, , 245-263.	1.7	0

#	ARTICLE	IF	CITATIONS
422	The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Gravesâ€™ Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	7
423	Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study. <i>Vaccines</i> , 2022, 10, 807.	2.1	3
424	Advances in Vaccine Development of the Emerging Novel Genotype Fowl Adenovirus 4. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
425	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
426	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. <i>Antiviral Research</i> , 2022, 203, 105345.	1.9	7
427	Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by 3 Doses of BBIBP-CorV Vaccination During One Year. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
428	Post-Vaccination Seropositivity Against SARS-CoV-2 in Peruvian Health Workers Vaccinated with BBIBP-CorV (Sinopharm). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
429	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. <i>Innovare Journal of Medical Sciences</i> , 0, , 6-13.	0.2	0
430	An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac). <i>Vaccines</i> , 2022, 10, 878.	2.1	4
432	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
433	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	21
435	Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. <i>Virologica Sinica</i> , 2022, , .	1.2	0
436	Thrombotic thrombocytopenia After Sinopharm BBIBPâ€™CorV COVIDâ€™19 vaccination. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12750.	1.0	15
437	Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 739-748.	5.2	82
438	Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 956.	2.1	8
440	Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
441	Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. <i>Vaccines</i> , 2022, 10, 944.	2.1	5
443	Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection. <i>Irish Journal of Medical Science</i> , 2023, 192, 731-739.	0.8	2

#	ARTICLE	IF	CITATIONS
444	Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. <i>Nature Communications</i> , 2022, 13, .	5.8	19
445	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33
446	Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity. <i>Vaccine</i> , 2022, 40, 4440-4452.	1.7	17
447	Immune Response to SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1464.	1.4	24
448	Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography. <i>Vaccines</i> , 2022, 10, 949.	2.1	0
449	Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. <i>Med</i> , 2022, , .	2.2	2
450	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. <i>International Journal of Medical Sciences</i> , 2022, 19, 1122-1130.	1.1	0
451	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. <i>Nature Communications</i> , 2022, 13, .	5.8	26
452	A Review on DNA Vaccines in Pre-Clinical Trials Against SARS-CoV-2. <i>Journal of Experimental Biology and Agricultural Sciences</i> , 2022, 10, 487-493.	0.1	4
453	Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
454	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
455	Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of Covid-19 disease. <i>International Journal of Transgender Health</i> , 2022, 15, 771-793.	1.1	1
456	A quantitative <i>RT-qPCR</i> for the detection of <i>SARS-CoV-2</i> and human gene in clinical application. <i>Microbial Biotechnology</i> , 0, , .	2.0	2
457	Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka. <i>Immunology</i> , 2022, 167, 275-285.	2.0	8
458	Predictive Risk Factors at Admission and a "Burning Point" During Hospitalization Serve as Sequential Alerts for Critical Illness in Patients With COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
459	Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
460	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. <i>Vaccines</i> , 2022, 10, 1071.	2.1	14
461	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
462	Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
463	SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. <i>Medical Microbiology and Immunology</i> , 2022, 211, 195-210.	2.6	8
464	Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud. <i>Horizonte MÃ©dico</i> , 2022, 22, e1937.	0.1	0
465	Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
466	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
467	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
468	Protective cellular and humoral immune responses to <i>Edwardsiella tarda</i> in flounder (<i>Paralichthys</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	8
469	Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1149.	2.1	7
470	Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2219-2233.	5.7	9
471	Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China. <i>Expert Review of Vaccines</i> , 2022, 21, 1465-1473.	2.0	3
472	Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
473	Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light. <i>Archives of Virology</i> , 2022, 167, 2181-2191.	0.9	9
474	Humoral immune response to COVID-19 infection or vaccination among celiac disease patients. <i>Central-European Journal of Immunology</i> , 2022, 47, 267-274.	0.4	1
475	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8485.	1.8	6
476	Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. <i>Vaccines</i> , 2022, 10, 1208.	2.1	5
477	Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
478	Self-adaptive virtual microchannel for continuous enrichment and separation of nanoparticles. <i>Science Advances</i> , 2022, 8, .	4.7	29
479	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6

#	ARTICLE	IF	CITATIONS
480	A prospective multicenter study on cutaneous reactions reported after Sinopharm <scp>COVID</scp> â€19 vaccination. <i>International Journal of Dermatology</i> , 0, , .	0.5	4
481	Vaccines platforms and COVID-19: what you need to know. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2022, 8, .	0.9	16
482	Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	6
483	New onset of acute uveitis following COVID-19 vaccination. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 0, , .	1.0	2
484	Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
485	Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants. <i>Vaccines</i> , 2022, 10, 1270.	2.1	12
486	Neutralizing antibodies to SARSâ€CoVâ€2 variants of concern including Delta and Omicron in subjects receiving mRNAâ€1273, BNT162b2, and Ad26.COVS vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
487	Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. <i>BMC Public Health</i> , 2022, 22, .	1.2	15
488	Recent advances in the vaccine development for the prophylaxis of SARS Covid-19. <i>International Immunopharmacology</i> , 2022, 111, 109175.	1.7	5
489	An Evaluation of Different Types of Peptone as Partial Substitutes for Animal-derived Serum in Vero Cell Culture. <i>ATLA Alternatives To Laboratory Animals</i> , 0, , 026119292211227.	0.7	2
490	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
492	Metabolic and Proteomic Profiles Associated with Immune Responses Induced by Different Inactivated SARS-CoV-2 Vaccine Candidates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10644.	1.8	1
493	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
494	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791.	2.6	5
496	<scp>COVID</scp> â€19 vaccination and male fertility issues: Myth busted. Is taking <scp>COVID</scp> â€19 vaccine the best choice for semen protection and male fertility from risky infection hazards?. <i>Andrologia</i> , 2022, 54, .	1.0	2
497	Third dose of anti-SARS-CoV-2 inactivated vaccine for patients with RA: Focusing on immunogenicity and effects of RA drugs. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
498	Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments. <i>Viruses</i> , 2022, 14, 1938.	1.5	7
499	Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus. <i>Pharmacological Reports</i> , 2022, 74, 1238-1254.	1.5	10

#	ARTICLE	IF	CITATIONS
500	Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice. <i>Archives of Virology</i> , 2022, 167, 2519-2528.	0.9	2
501	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. <i>ACS Infectious Diseases</i> , 2022, 8, 2119-2132.	1.8	1
502	Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100752.	3.3	14
503	Analysis of SARS-CoV-2 viral loads in stool samples and nasopharyngeal swabs from COVID-19 patients in the United Arab Emirates. <i>PLoS ONE</i> , 2022, 17, e0274961.	1.1	10
504	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
505	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. <i>DARU, Journal of Pharmaceutical Sciences</i> , 0, , .	0.9	5
507	A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
508	Long-Term Antibody Response to SARS-CoV-2 in Children. <i>Journal of Clinical Immunology</i> , 2023, 43, 46-56.	2.0	8
510	Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
511	Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBP-CorV vaccination during one year. <i>Proteomics</i> , 0, , 2200306.	1.3	2
512	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
513	Herpetic endotheliitis and stromal keratitis following inactivated COVID-19 vaccination. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	4
514	A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 661-670.	3.6	4
515	A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues. <i>Computer Communications</i> , 2023, 197, 34-51.	3.1	13
516	Observational study of antibody levels after second and third SARS-CoV-2 vaccinations in medical workers. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	1
517	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
518	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 1541-1573.	1.4	4
519	Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	5

#	ARTICLE	IF	CITATIONS
520	An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	38
523	Single-nucleus transcriptomic profiling of multiple organs in a rhesus macaque model of SARS-CoV-2 infection. <i>Zoological Research</i> , 2022, 43, 1041-1062.	0.9	8
524	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
525	Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14663.	1.2	3
526	Pilot genome-wide association study of antibody response to inactivated SARS-CoV-2 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
527	Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
528	The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
529	Psychiatric symptoms before and after COVID-19 vaccination: A cohort study of hospitalized schizophrenia patients. <i>Asian Journal of Psychiatry</i> , 2022, 78, 103319.	0.9	3
530	Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine. <i>Innovation(China)</i> , 2023, 4, 100359.	5.2	4
531	Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm). <i>Travel Medicine and Infectious Disease</i> , 2023, 52, 102514.	1.5	3
532	Ethnological aspects of COVID-19. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
533	Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study. <i>Diabetes Therapy</i> , 2023, 14, 139-151.	1.2	4
534	Long-read assembly of major histocompatibility complex and killer cell immunoglobulin-like receptor genome regions in cynomolgus macaque. <i>Biology Direct</i> , 2022, 17, .	1.9	2
535	Current state of, prospects for, and obstacles to mRNA vaccine development. <i>Drug Discovery Today</i> , 2023, 28, 103458.	3.2	5
536	Comparative multiomics analysis of cell physiological state after culture in a basket bioreactor. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
537	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
539	Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants. <i>Heliyon</i> , 2022, 8, e12594.	1.4	1
540	COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. <i>Cell Discovery</i> , 2022, 8, .	3.1	3

#	ARTICLE	IF	CITATIONS
541	Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. <i>Virology Journal</i> , 2022, 19, .	1.4	14
542	Nanotechnology in COVID-19 Vaccines. , 2023, , 14-26.		0
543	Lower limb lymphedema and cellulitis as a complication of COVID-19 vaccine: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	0
544	COVID-19 vaccines and a perspective on Africa. <i>Trends in Immunology</i> , 2023, 44, 172-187.	2.9	4
545	Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	0
546	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.	1.9	1
547	A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
548	From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114208.	2.5	9
549	Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury. <i>International Journal of Biological Macromolecules</i> , 2023, 228, 715-731.	3.6	4
550	The use of quantitative enzyme-linked immunosorbent assay for the determination of S-antigen concentration in whole-virion inactivated adsorbed coronavirus vaccines. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 405-413.	0.2	0
551	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
552	Repeat-Dose Toxicity of Candidate Omicron COVID-19 Vaccine in Sprague-Dawley Rats. <i>Covid</i> , 2023, 3, 51-64.	0.7	0
553	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299.	2.1	5
554	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
555	Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
556	Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021. <i>Travel Medicine and Infectious Disease</i> , 2023, 53, 102565.	1.5	2
557	Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin – A review. <i>Inorganic Chemistry Communication</i> , 2023, 152, 110682.	1.8	4
558	Viruses as biomaterials. <i>Materials Science and Engineering Reports</i> , 2023, 153, 100715.	14.8	4

#	ARTICLE	IF	CITATIONS
559	Ferrets: A powerful model of SARS-CoV-2. <i>Zoological Research</i> , 2023, 44, 323-330.	0.9	1
560	Review on COVID-19 Vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5868-5874.	0.2	0
561	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	1.5	1
562	Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine. <i>Biosafety and Health</i> , 2023, 5, 89-100.	1.2	4
563	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968.	1.7	17
564	Application of Traditional Vaccine Development Strategies to SARS-CoV-2. <i>MSystems</i> , 2023, 8, .	1.7	7
565	Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. <i>Antiviral Research</i> , 2023, 212, 105556.	1.9	2
566	Molecular Characterization and Selection of Indigenous SARS-CoV-2 Delta Variant for the Development of the First Inactivated SARS-CoV-2 Vaccine of Pakistan. <i>Vaccines</i> , 2023, 11, 607.	2.1	1
567	Development and Evaluation of Recombinant B-Cell Multi-Epitopes of PDHA1 and GAPDH as Subunit Vaccines against <i>Streptococcus iniae</i> Infection in Flounder (<i>Paralichthys olivaceus</i>). <i>Vaccines</i> , 2023, 11, 624.	2.1	3
568	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
569	Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination. <i>Vaccines</i> , 2023, 11, 704.	2.1	0
570	Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.	1.6	1
571	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
572	Investigation of the inhibitory activity of extracts, fractions and secondary metabolites of <i>Silene</i> spp. (<i>Caryophyllaceae</i>) and <i>Serratula cupuliformis</i> (<i>Asteraceae</i>) on the replication of SARS-CoV-2 coronavirus. <i>South of Russia: Ecology, Development</i> , 2023, 18, 62-81.	0.1	0
573	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	5.8	12
574	Generalized Pustular Psoriasis Flare-Up after Both Doses of BBIBP-CorV Vaccination in a Patient under Adalimumab Treatment: A Case Report. <i>Case Reports in Dermatology</i> , 2023, 15, 61-65.	0.3	2
583	Therapeutic Interventions for COVID-19. , 0, , .		0
593	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0

#	ARTICLE	IF	CITATIONS
611	Passive antibody therapy in emerging infectious diseases. <i>Frontiers of Medicine</i> , 2023, 17, 1117-1134.	1.5	2
615	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	1.5	0